Eli Lilly (NYSE: LLY) has been on a roll in recent years, thanks to its leadership in the weight management drug market.

Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than ...

The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

The lawsuit alleges insulin can cost Eli Lilly just a few dollars to produce, while some consumers are charged hundreds of ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

The about-$1 billion deal could come imminently.

A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it ...

Nvidia Corp. plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...